This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
EchoSolv, the groundbreaking AI platform developed by Echo IQ, is revolutionizing the detection of aortic stenosis. With its unparalleled access to extensive echocardiographic data and AI-driven analysis, EchoSolv empowers clinicians to identify aortic stenosis earlier and with greater accuracy.
24 and how those may impact clinical practice and patientcare in this deep dive clinical trial session. 24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m. ET Murphy Ballroom 4 ACC.24
Last week marked a significant milestone as the center of excellence for Transcatheter Aortic Valve Implantation (TAVI) procedures hosted a highly successful TAVI Masterclass. Spearheaded by the eminent Prof. Under the guidance of Prof. The success of the TAVI Masterclass would not have been possible without the visionary leadership of Prof.
At ADN CoE, we are dedicated to empowering medical professionals through a diverse range of fellowship programs meticulously crafted to nurture expertise and innovation. This testimonial exemplifies the commitment to excellence and innovation that defines our fellowship programs.
Last week marked a significant milestone as the center of excellence for Transcatheter Aortic Valve Implantation (TAVI) procedures hosted a highly successful TAVI Masterclass. Spearheaded by the eminent Prof. Under the guidance of Prof. The success of the TAVI Masterclass would not have been possible without the visionary leadership of Prof.
The field of cardiology is constantly changing, with new techniques and technologies emerging to enhance care. One such innovation is the Transcatheter Aortic Valve Implantation (TAVI) which has the potential to revolutionize the treatment of valve disease by offering an invasive option compared to traditional open heart surgery.
The field of cardiology is constantly changing, with new techniques and technologies emerging to enhance care. One such innovation is the Transcatheter Aortic Valve Implantation (TAVI) which has the potential to revolutionize the treatment of valve disease by offering an invasive option compared to traditional open heart surgery.
This fellowship also will allow Dr. Fiedler and Dr. Folesani to learn novel techniques, adapt innovative technology, and receive training from expert mentors who are dedicated to the highest standards of cardiothoracic surgery. She will study under Stephen Large, MD, MA, FRCS, at Royal Papworth Hospital in Cambridge, England.
“Cardiovascular care is not one size fits all and by fostering representation of broader perspectives within cardiovascular clinical trial leadership roles, the ACC’s Clinical Trials Research Program will ensure the data that drives patientcare more closely reflects the needs of actual cardiovascular patients.”
At ADN CoE, we are dedicated to empowering medical professionals through a diverse range of fellowship programs meticulously crafted to nurture expertise and innovation. This testimonial exemplifies the commitment to excellence and innovation that defines our fellowship programs.
Through real multi-specialty collaboration, this summit will not only advance our knowledge but also directly impact patientcare worldwide." Our goal is to unite specialists from every corner of cardiovascular care to extend the heart team, redefine innovations, and develop new standards for managing valve patients."
Through real multi-specialty collaboration, this summit will not only advance our knowledge but also directly impact patientcare worldwide." Our goal is to unite specialists from every corner of cardiovascular care to extend the heart team, redefine innovations, and develop new standards for managing valve patients."
When providers and clinicians have access to the best quality data, patientcare improves. This data linkage would help us tailor the right treatments for the right patients and even help project outcomes far into the future.” “I'm proud to co-lead the Meaningful Access to Federal Health Plan Claims Data Act,” said Rep.
The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine.
mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patientcare through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. billion.
This two-day training not only set the tone for a year of growth and innovation but also underscored ADN CoEs commitment to advancing cardiology education through cutting-edge methodologies. Introducing innovative technologies. Building a global community of cardiology professionals dedicated to improving patientcare.
The combination of AI-ECG with UltraSights AI-guided focused cardiac ultrasound (FoCUS) increased the positive predictive value (PPV) from 48% to 96% for identifying reduced left ventricular ejection fraction (LVEF) or significant aortic valve disease. Scans were completed in under five minutes on average.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content